Which glycopeptide antibiotic is used for skin and skin structure infections caused by resistant Gram-positive bacteria?

Dalbavancin (Dalvance) is the correct choice for treating skin and skin structure infections caused by resistant Gram-positive bacteria due to its unique properties and clinical indications. It is a long-acting glycopeptide antibiotic that offers a convenient dosing schedule, often allowing for infusion once a week, which is particularly beneficial for outpatient management of skin infections.

Dalbavancin has demonstrated efficacy against a range of resistant Gram-positive pathogens, including Methicillin-resistant Staphylococcus aureus (MRSA), making it a valuable option in the face of rising resistance rates. Its mechanism of action involves inhibiting cell wall synthesis, which is critical for the growth and replication of bacteria.

While vancomycin is also a glycopeptide with similar activity against Gram-positive bacteria, it may not be as effective for certain forms of resistant infections and has a more frequent dosing regimen. Teicoplanin, while used in some regions, may have limited use in specific healthcare settings compared to dalbavancin. Oritavancin, another long-acting glycopeptide, is effective and has a single-dose treatment option, but dalbavancin is more specifically indicated for outpatient therapy for skin infections, contributing to its selection in this scenario.

Thus,